Cell-Based Therapy Training Program for Incumbent Workers

In the past decade, with the rapid development of cell therapies, the U.S. biopharmaceutical industry has made major advancements to cure some of society’s most devastating cancers and diseases. Unlike traditional or protein biopharmaceuticals, cell therapy manufacturing involves manipulating either the patient’s own cells—i.e., autologous therapy—or a donor’s cells—i.e., allogenic therapy—to fight the disease. Yet advancements in the commercialization of treatments and the establishment of large-scale manufacturing have been impeded due to workforce shortages. Across the country, a lack of training programs that cater to incumbent workers in the cell therapy sector has slowed the workforce pipeline.